Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Halozyme Therapeutics: Q4 Earnings Snapshot
Halozyme Therapeutics: Q4 Earnings Snapshot
Associated Press Finance
Wed, February 18, 2026 at 6:19 AM GMT+9 1 min read
In this article:
HALO
+1.31%
SAN DIEGO (AP) — SAN DIEGO (AP) — Halozyme Therapeutics Inc. (HALO) on Tuesday reported a loss of $141.6 million in its fourth quarter.
On a per-share basis, the San Diego-based company said it had a loss of $1.20. Losses, adjusted for one-time gains and costs, were 24 cents per share.
The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for earnings of $2.15 per share.
The biopharmaceutical company posted revenue of $451.8 million in the period, which topped Street forecasts. Four analysts surveyed by Zacks expected $448.6 million.
For the year, the company reported profit of $316.9 million, or $2.56 per share. Revenue was reported as $1.4 billion.
Halozyme Therapeutics expects full-year earnings in the range of $7.75 to $8.25 per share, with revenue in the range of $1.71 billion to $1.81 billion.
This story was generated by Automated Insights () using data from Zacks Investment Research. Access a Zacks stock report on HALO at
Terms and Privacy Policy
Privacy Dashboard
More Info